AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously presented) A percutaneously absorbable preparation comprising sodium diclofenac and ammonium chloride, wherein the ammonium chloride is blended at the range of from 0.5 to 10 fold (mole/mole) based on the sodium diclofenac.

2. – 3. (Cancelled).

4. (Previously presented) The percutaneously absorbable preparation according to claim 1, wherein the percutaneously absorbable preparation is a nonaqueous preparation.

5. (Previously presented) The percutaneously absorbable preparation according to claim 1, wherein the percutaneously absorbable preparation is a patch comprising a matrix, or an ointment.

6. (Cancelled)

7. (Previously presented) The percutaneously absorbable preparation according to claim 1, wherein the ammonium chloride is combined at the range of from 0.5 to 7 fold (mole/mole) based on the sodium diclofenac.

8. (Previously presented) The percutaneously absorbable preparation according to any one of claims 1, 4-5 or 7, which is a percutaneously absorbable matrix preparation, wherein the sodium diclofenac and the ammonium chloride are contained in an adhesive base layer.

9. (Previously presented) The percutaneously absorbable preparation according to claim 8, wherein the adhesive base layer is composed of one or more than two of styrene-isoprene-styrene block copolymer, polyisobutylene, and acrylic adhesive.

10. (Previously presented) A percutaneous absorption accelerating composition of sodium diclofenac, which contains ammonium chloride, wherein the ammonium chloride is blended at the range of from 0.5 to 10 fold (mole/mole) based on the sodium diclofenac.

11. – 12. (Cancelled)

13. (New) A method for improving the percutaneous absorbability of sodium diclofenac in a non-aqueous percutaneously absorbable preparation, the method comprising providing ammonium chloride in the preparation at a range of from 0.5 to 10 fold mole/mole based on the sodium diclofenac.

14. (New) The method according to claim 13, wherein ammonium chloride is blended at a range of from 0.5 to 7 fold mole/mole based on the sodium diclofenac.

15. (New) The method according to claim 13, wherein the non-aqueous percutaneously absorbable preparation is a patch comprising a matrix or an ointment.

16. (New) The method according to claim 13, wherein the sodium diclofenac and the ammonium chloride are contained in an adhesive base layer.

17. (New) The method according to claim 16, wherein the adhesive base layer is composed of one or more than two of styrene-isoprene-styrene block copolymer, polyisobutylene, and acrylic adhesive.